

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Shi N, Hiraga N, <u>Imamura M</u> , Hayes CN, Zhang Y, Kosaka K, Okazaki A, Murakami E, Tsuge M, Abe H, Aikata H, Takahashi S, Ochi H, Tateno-Mukaidani C, Yoshizato K, Matsui H, Kanai A, Inaba T, McPhee F, Gao M, Chayama K	Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.	Gut	62	1055-61	2013
Abe H, Hayes CN, Hiraga N, <u>Imamura M</u> , Tsuge M, Miki D, Takahashi S, Ochi H, Chayama K.	A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing	Am J Gastroenterol	108	1464-72	2013
Kosaka K, Hiraga N, <u>Imamura M</u> , Yoshimi S, Murakami E, Nakahara T, Honda Y, Ono A, Kawaoka T, Tsuge M, Abe H, Nelson Hayes C, Miki D, Aikata H, Ochi H, Ishida Y, Tateno C, Yoshizato K, Sasaki T, Chayama K	A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections	Biochem Biophys Res Commun	441	230-5	2013
Hayes CN, Imamura M, Aikata H, <u>Chayama K</u>	Genetics of IL28B and HCV-response to infection and treatment.	Nat Rev Gastroenterol Hepatol	9(7)	406-17	2012
<u>Chayama K</u> , Hayes CN, <u>Imamura M</u> .	Impact of interleukin-28B genotype on in vitro and in vivo systems of hepatitis C virus replication	Hepatol Res	42(9)	841-53	2012
Miki D, Ohishi W, Ochi H, Hayes CN, Abe H, Tsuge M, Imamura M, Kamatani N, Nakamura Y, <u>Chayama K</u> .	Serum PAI-1 is a novel predictor for response to pegylated interferon- α -2b plus ribavirin therapy in chronic hepatitis C virus infection.	J Viral Hepat	19(2)	e126-e133	2012
Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL.	Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor	Nat Med	18(2)	281-5	2012
Hiraga N, Abe H, <u>Imamura M</u> , Tsuge M, Takahashi S, Hayes CN, Ochi H, Tateno C, <u>Yoshizato K</u> , Nakamura Y, Kamatani N, <u>Chayama K</u>	Impact of viral amino acid substitutions and host IL28B polymorphism on replication and susceptibility to interferon of hepatitis C virus.	Hepatology	54(3)	764-71	2011

Hiraga N, <u>Imamura M</u> , Abe H, Nelson Hayes C, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, <u>Yoshizato K</u> , Matsui H, Kanai A, Inaba T, Tanaka S, <u>Chayama K</u> .	Rapid emergence of telaprevir resistant hepatitis C virus strain from wild type clone in vivo.	Hepatology	54(3)	781-88	2011
<u>Chayama K</u> , Hayes CN, Hiraga N, Abe H, Tsuge M, <u>Imamura M</u> .	Animal model for study of human hepatitis viruses.	J Gastroenterol Hepatol.	26	13-18s	2011
Tsuge M, Fujimoto Y, Hiraga N, Zhang Y, Ohnishi M, Kohno T, Abe H, Miki D, <u>Imamura M</u> , Takahashi S, Ochi H, Hayes CN, Miya F, Tsunoda T, <u>Chayama K</u> .	Hepatitis C virus response in the liver of the human hepatocyte chimeric mouse.	PLoS One.	6	e23856.	2011
Tsuge M, Takahashi S, Hiraga N, Fujimoto Y, Zhang Y, Mitsui F, Abe H, Kawaoka T, <u>Imamura M</u> , Ochi H, Hayes CN, <u>Chayama K</u> .	Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice.	J Infect Dis	2	224-8	2011
Saeed M, Shiina M, Date T, Akazawa D, Watanabe N, Murayama A, Suzuki T, Watanabe H, Hiraga N, <u>Imamura M</u> , <u>Chayama K</u> , Choi Y, Krawczynski K, Liang TJ, <u>Wakita T</u> , Kato T.	In Vivo adaptation of hepatitis C virus for efficient virus production and evasion of apoptosis.	Hepatology	54(2)	425-33	2011
Ohara E, Hiraga N, <u>Imamura M</u> , Iwao E, Kamiya N, Yamada I, Kono T, Onishi M, Hirata D, Mitsui F, Kawaoka T, Tsuge M, Takahashi S, Abe H, Hayes CN, Ochi H, Tateno C, <u>Yoshizato K</u> , Tanaka S, <u>Chayama K</u> .	Elimination of Hepatitis C Virus by Short Term NS3-4A and NS5B Inhibitor Combination Therapy in Human Hepatocyte Chimeric Mice.	J Hepatol	54(5)	872-8	2011
Abe H, <u>Imamura M</u> , Hiraga N, Tsuge M, Mitsui F, Kawaoka T, Takahashi S, Ochi H, Maekawa T, Hayes CN, Tateno C, <u>Yoshizato K</u> , Murakami S, Yamashita N, Matsuhira T, Asai K, <u>Chayama K</u> .	ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.	J Hepatol	55(1)	11-8	2011
Hata T, Uemoto S, Fujimoto Y, Murakami T, Tateno C, <u>Yoshizato K</u> , Kobayashi E.	Transplantation of engineered chimeric liver with autologous hepatocytes and xenobiotic scaffold.	Ann Surg	257(3)	542-7	2013
Tanaka F, Tominaga K, Sasaki E, Sogawa M, Yamagami H, Tanigawa T, Shiba M, Watanabe K, Watanabe T, Fujiwara Y, Kawada N, <u>Yoshizato K</u> , Arakawa T.	Cytoglobin May Be Involved in the Healing Process of Gastric Mucosal Injuries in the Late Phase Without Angiogenesis.	Dig Dis	Jan 10.	Epub ahead of print	2013

Kosaka K, Hiraga N, Imamura M, Yoshimi S, Murakami E, Nakahara T, Honda Y, Ono A, Kawaoka T, Tsuge M, Abe H, Hayes CN, Miki D, Aikata H, Ochi H, Ishida Y, Tateno C, <u>Yoshizato K</u> , Sasaki T, Chayama K.	A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.	Biochem Biophys Res Commun	Nov;8 441(1)	230-5	2013
<u>Yoshizato K</u> , Tateno C.	A mouse with humanized liver as an animal model for predicting drug effects and for studying hepatic viral infection: where to next?	Expert Opin Drug Metab Toxicol	Nov;9(11)	1419-35	2013
Tachibana A, Tateno C, <u>Yoshizato K</u> .	Repopulation of the immunosuppressed retrorsine-treated infant rat liver with human hepatocytes.	Xenotrans plantation	Jul-Aug; 20(4)	227-38	2013
Shi N, Hiraga N, Imamura M, Hayes CN, Zhang Y, Kosaka K, Okazaki, Murakami E, Tsuge M, Abe H, Aikata H, Takahashi S, Ochi H Tateno-Mukaidani C <u>Yoshizato K</u> , Matsui H, Kanai A, Inaba T, McPhee F, Gao M, Chayama K.	Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.	Gut	Jul 62(7)	1055-61	2013
Tateno C, Miya F, Wake K, Kataoka M, Ishida Y, Yamasaki C, Yanagi A, Kakuni M, Wisse E, Verheyen F, Inoue K, Sato K, Kudo A, Arie S, Itamoto T, Asahara T, Tsunoda T, <u>Yoshizato K</u> .	Morphological and microarray analyses of human hepatocytes from xenogeneic host livers.	Lab Invest	Jan 93(1)	54-71	2013
Fujiwara S, Fujioka H, Tateno C, Taniguchi K, Ito M, Ohishi H, Utoh R, Ishibashi H, Kanematsu T, <u>Yoshizato K</u> .	A novel animal model for in vivo study of liver cancer metastasis.	World J Gastroent erol	Aug 7 18(29)	3875-82	2012
Izuka M, Ogawa T, Enomoto M, Motoyama H, <u>Yoshizato K</u> , Ikeda K, Kawada N.	Induction of microRNA-214-5p in human and rodent liver fibrosis.	Fibrogene sis Tissue Repair	Aug 1 5(1)	12	2012
Tatsumi K, Ohashi K, Tateno C, <u>Yoshizato K</u> , Yoshioka A, Shima M, Okano T.	Human hepatocyte propagation system in the mouse livers: functional maintenance of the production of coagulation and anticoagulation factors.	Cell Transplant	21(2-3)	437-45	2012

Ohashi K, Tatsumi K, Tateno C, Kataoka M, Utoh R, Yoshizato K, Okano T.	Liver tissue engineering utilizing hepatocytes propagated in mouse livers in vivo.	Cell Transplant	21(2-3)	429-36	2012
Okazaki A, Hiraga N, Imamura M, Hayes CN, Tsuge M, Takahashi S, Aikata H, Abe H, Miki D, Ochi H, Tateno C, <u>Yoshizato K</u> , Ohdan H, Chayama K.	Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse.	Hepatology	Aug 56(2)	555-66	2012
Ogawa T, Enomoto M, Fujii H, Sekiya Y, <u>Yoshizato K</u> , Ikeda K, Kawada N.	MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis.	Gut	Nov 61(11)	1600-9	2012
<u>Yoshizato K</u> , Tateno C, Utoh R.	Mice with liver composed of human hepatocytes as an animal model for drug testing.	Curr Drug Discov Technol	Mar 9(1)	63-76	2012
Sekiya Y, Ogawa T, <u>Yoshizato K</u> , Ikeda K, Kawada N.	Suppression of hepatic stellate cell activation by microRNA-29b.	Biochem Biophys Res Commun	Aug 19 412(1)	74-9	2011
Sekiya Y, Ogawa T, Iizuka M, <u>Yoshizato K</u> , Ikeda K, Kawada N.	Down-regulation of cyclin E1 expression by microRNA-195 accounts for interferon- β -induced inhibition of hepatic stellate cell proliferation.	J Cell Physiol	Oct 226(10)	2535-42	2011
Thuy le TT, Morita T, Yoshida K, Wakasa K, Iizuka M, Ogawa T, Mori M, Sekiya Y, Momen S, Motoyama H, Ikeda K, <u>Yoshizato K</u> , Kawada N.	Promotion of liver and lung tumorigenesis in DEN-treated cytoglobin-deficient mice.	Am J Pathol	Aug 179(2)	1050-60	2011
Hiraga N, Imamura M, Abe H, Hayes CN, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, <u>Yoshizato K</u> , Matsui H, Kanai A, Inaba T, Tanaka S, Chayama K.	Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.	Hepatology	Sep 2 54(3)	781-8	2011
Hiraga N, Abe H, Imamura M, Tsuge M, Takahashi S, Hayes CN, Ochi H, Tateno C, <u>Yoshizato K</u> , Nakamura Y, Kamatani N, Chayama K.	Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.	Hepatology	Sep 2 54(3)	764-71	2011
Amano H, Hino H, Tateno C, Emoto K, Imaoka Y, Yamasaki C, Itamoto T, Tashiro H, Asahara T, Ohdan H, <u>Yoshizato K</u> .	Therapeutic potential of propagated hepatocyte transplantation in liver failure.	J Surg Res	May 167(1)	e29-37	2011

Tateno C, Kataoka M, Utoh R, Tachibana A, Itamoto T, Asahara T, Miya F, Tsunoda T, <u>Yoshizato K.</u>	Growth hormone-dependent pathogenesis of human hepatic steatosis in a novel mouse model bearing a human hepatocyte-repopulated liver	Endocrinology	Apr 152(4)	1479-91	2011
Abe H, Imamura M, Hiraga N, Tsuge M, Mitsui F, Kawaoka T, Takahashi S, Ochi H, Maekawa T, Hayes CN, Tateno C, <u>Yoshizato K.</u> , Murakami S, Yamashita N, Matsuhira T, Asai K, Chayama K.	ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo	J Hepatol	Jul 55(1)	11-8	2011
Ohara E, Hiraga N, Imamura M, Iwao E, Kamiya N, Yamada I, Kono T, Onishi M, Hirata D, Mitsui F, Kawaoka T, Tsuge M, Takahashi S, Abe H, Hayes CN, Ochi H, Tateno C, <u>Yoshizato K.</u> , Tanaka S, Chayama K.	Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice.	J Hepatol	May 54(5)	872-8	2011
A Seki, S Y akai, T Komura, A Nasti, K Yoshida, M Higashimoto, M Honda, S Usui, M Takamura, T Takamura, T Ochiya, K Furuichi, T Wada, <u>S Kaneko.</u>	Adipose tissue-derived stem cells as a regenerative therapy for a mouse steatohepatitis-induced cirrhosis model.	Hepatology	58(3)	1133-42	2013
T Shirasaki, M Honda, T Shimakami, R Horii, T Yamashita, Y Sakai, A Sakai, H Okada, R Watanabe, S Murakami, M Yi, SM Lemon, <u>S Kaneko.</u>	MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells.	J Virol	87(9)	5270-86	2013
T Yamashita, M Honda, Y Nakamoto, M Baba, K Nio, Y Hara, SS Zeng, TH Kondo, H Takatori, T Yamashita, E Mizukoshi, H Ikeda, Y Zen, H Takamura, XW Wang, <u>S Kaneko.</u>	Discrete nature of EpCAM(+) and CD90(+) cancer stem cells in human hepatocellular carcinoma.	Hepatology	57(4)	11484-97	2013
H Okada, M Honda, JS Campbell, Y Sakai, T Yamashita, Y Takebuchi, K Hada, T Shirasaki, R Takabatake, M Nakamura, H Sunakozaka, T Tanaka, N Fausto, <u>S Kaneko.</u>	Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development.	Cancer Res	72(17)	4459-71	2012
M Honda, K Takehana, A Sakai, Y Tagata, T Shirasaki, S Nishitani, T Muramatsu, T Yamashita, Y Nakamoto, E Mizukoshi, Y Sakai, T Yamashita, M Nakamura, T Shimakami, M Yi, SM Lemon, T Suzuki, T Wakita, <u>S Kaneko;</u> Hokuriku Liver Study Group.	Malnutrition Impairs Interferon Signaling through mTOR and FoxO pathways in Patients with Chronic Hepatitis C.	Gastroenterology	141(1)	128-140	2011
Abe Y., Aly H. H., Hiraga N., Imamura M., Wakita T., Shimotohno K., Chayama K., <u>Hijikata M.</u>	Thromboxane A ₂ synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers	Gastroenterology	145	658-667	2013

Kuroki M., Ariumi Y., <u>Hijikata M.</u> , Ikeda M., Dansako H., Wakita T., Shimotohno K., Kato N.	PML tumor suppressor protein is required for HCV production	Biochem. Biophys. Res. Commun.	430	592-597	2013
Aly H.H., Shimotohno K., <u>Hijikata M.</u> , Seya T.	In vitro models for the analysis of HCV life cycle.	Microbiol. and Immunol.	56(1)	1-9	2012
Wakita T., Suzuki T., Evans M.J., Shimotohno K., Chayama K., Matsuura Y., <u>Hijikata M.</u> , Moriishi K., Seya T., Enomoto N., Koike K., Kato N., Kanto T., Hotta H.	Will there be an HCV meeting in 2020? Summary of the 17 th International Meeting in Hepatitis C Virus and Related Viruses	Gastroenterology	141(1)	E1-E5	2011
Ariumi, Y. Misao Kuroki M., Kushima Y., Osugi K., <u>Hijikata M.</u> , Maki M., Ikeda M., Kato N.	Hepatitis C virus hijacks P-body and stress granule components around lipid droplets.	J. Virol.,	85(14)	6882-6892	2011
Takahashi Y, Ando M, Nishikawa M, Hiraga N, Imamura M, Chayama K, <u>Takakura Y.</u>	Long-Term Elimination of Hepatitis C Virus from Human Hepatocyte Chimeric Mice After Interferon- γ Gene Transfer.	Hum Gene Ther Clin Dev.	In press		2013
Uno S, Nishikawa M, Mohri K, Umeki Y, Matsuzaki N, Takahashi Y, Fujita H, Kadowaki N, <u>Takakura Y.</u>	Efficient delivery of immunostimulatory DNA to mouse and human immune cells through the construction of polyiod-like structured DNA.	Nanomedicine	In press		2013
Mukumoto H, Takahashi Y, Ando M, Nishikawa M, <u>Takakura Y.</u>	Expression profile-dependent improvement of insulin sensitivity by gene delivery of interleukin-6 in a mouse model of type II diabetes.	Mol Pharm.	10(10)	3812-3821	2013
Miyakawa N, Nishikawa M, Takahashi Y, Ando M, Misaka M, Watanabe Y, <u>Takakura Y.</u>	Gene delivery of albumin binding peptide-interferon γ fusion protein with improved pharmacokinetic properties and sustained biological activity.	J Pharm Sci.	102(9)	3110-3118	2013
Watcharanurak K, Nishikawa M, Takahashi Y, <u>Takakura Y.</u>	Controlling the kinetics of interferon transgene expression for improved gene therapy	J Drug Target	20(9)	764-769	2012
Watcharanurak K, Nishikawa M, Takahashi Y, Kabashima K, Takahashi R, <u>Takakura Y.</u>	Regulation of immunological balance by sustained interferon- γ gene transfer for acute phase of atopic dermatitis in mice.	Gene Ther	20(5)	538-544	2013
Ando M, Takahashi Y, Nishikawa M, Watanabe Y, <u>Takakura Y.</u>	Constant and steady transgene expression of interferon- γ by optimization of plasmid construct for safe and effective interferon- γ gene therapy.	J Gene Med	14(4)	288-295	2012

Takahashi Y, Nishikawa M, <u>Takakura Y.</u>	Development of safe and effective nonviral gene therapy by eliminating CpG motifs from plasmid DNA vector	Front Biosci (Schol Ed)	4	133-141	2009
Takahashi Y, Nishikawa M, Takiguchi N, Suehara T, <u>Takakura Y.</u>	Saturation of transgene protein synthesis from mRNA in cells producing a large number of transgene mRNA.	Biotechnol Bioeng	In press		2011
Miura <u>Maekawa S</u> , Sato M, Komatsu N, Tatsumi A, Takano S, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Enomoto N.	Deep sequencing analysis of variants resistant to the NS5A inhibitor docalatasvir in patients with genotype 1b hepatitis C virus infection.	Hepatol Res.	Feb	In press	2014
Komatsu N, Motosugi U, <u>Maekawa S</u> , Shindo K, Sakamoto M, Sato M, Tatsumi A, Miura M, Amemiya F, Nakayama Y, Inoue T, Fukasawa M, Uetake T, Ohtaka M, Sato T, Asahina Y, Kurosaki M, Izumi N, Ichikawa T, Araki T, Enomoto N.	Hepatocellular carcinoma risk assessment using gadoxetic acid-enhanced hepatocyte phase magnetic resonance imaging.	Hepatol Res.	Feb	In press	2014
Shen H, Yamashita A, Nakakoshi M, Yokoe H, Sudo M, Kasai H, Tanaka T, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Shindo H, <u>Maekawa S</u> , Enomoto N, Tsubuki M, Moriishi K.	Inhibitory effects of caffeic Acid phenethyl ester derivatives on replication of hepatitis C virus.	PLoS One.	17;8(12)	e82299.	2013
<u>Maekawa S</u> , Enomoto N.	Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C.	J Gastroenterol.	Jan;49(1)	163-4.	2014
Miura M, <u>Maekawa S</u> , Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.	Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression.	J Virol.	87(23)	12541-51.	2013

Shindo H, <u>Maekawa S</u> , Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.	IL-28B (IFN- λ 3) and IFN- α synergistically inhibit HCV replication.	J Viral Hepat.	20(4)	281-9.	2013
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, <u>Maekawa S</u> , Tokunaga K, Mizokami M, Izumi N.	Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.	J Med Virol.	85(3)	449-58.	2013
Komase K, <u>Maekawa S</u> , Miura M, Sueki R, Kadokura M, Shindo H, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.	Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C.	Hepatol Res.	43(8)	865-75.	2013
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Matsuura K, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, <u>Maekawa S</u> , Tokunaga K, Mizokami M, Izumi N.	Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.	J Med Virol.	85(3)	449-58.	2013
Fujimoto Y, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Ikeda M, Kato N, Sakamoto N, <u>Maekawa S</u> , Enomoto N, de Voogd NJ, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Yamashita A, Tanaka J, Moriishi K.	Inhibition of both protease and helicase activities of hepatitis C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp.	PLoS One.	7(11)	e48685.	2012

Sueki R, <u>Maekawa S</u> , Miura M, Kadokura M, Komase K, Shindo H, Kanayama A, Ohmori T, Shindo K, Amemiya F, Nakayama Y, Uetake T, Inoue T, Sakamoto M, Enomoto N.	Correlation between pretreatment viral sequences and the emergence of lamivudine resistance in hepatitis B virus infection.	J Med Virol.	84(9)	1360-8.	2012
Yamashita A, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Fujita Y, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, <u>Maekawa S</u> , Enomoto N, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Tanaka J, Moriishi K.	Inhibition of hepatitis C virus replication and viral helicase by ethyl acetate extract of the marine feather star <i>Alloeocomatella polycladia</i> .	Mar Drugs.	10(4)	744-61.	2012
<u>Maekawa S</u> , Sakamoto M, Miura M, Kadokura M, Sueki R, Komase K, Shindo H, Komatsu N, Shindo K, Kanayama A, Ohmori T, Amemiya F, Takano S, Yamaguchi T, Nakayama Y, Kitamura T, Inoue T, Okada S, Enomoto N.	Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.	Hepatolog y.	56(5)	1611-21.	2012
Miura M, <u>Maekawa S</u> , Kadokura M, Sueki R, Komase K, Shindo H, Ohmori T, Kanayama A, Shindo K, Amemiya F, Nakayama Y, Kitamura T, Uetake T, Inoue T, Sakamoto M, Okada S, Enomoto N.	Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C.	Hepatol Int.	6(1)	386-396.	2012
Shindo H, <u>Maekawa S</u> , Komase K, Sueki R, Miura M, Kadokura M, Shindo K, Amemiya F, Kitamura T, Nakayama Y, Inoue T, Sakamoto M, Okada SI, Asahina Y, Izumi N, Honda M, Kaneko S, Enomoto N.	Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients.	Hepatol Int.	6(2)	482-490.	2012

Takaya D, Yamashita A, Kamijo K, Gomi J, Ito M, <u>Maekawa S</u> , Enomoto N, Sakamoto N, Watanabe Y, Arai R, Umeyama H, Honma T, Matsumoto T, Yokoyama S.	A new method for induced fit docking (GENIUS) and its application to virtual screening of novel HCV NS3-4A protease inhibitors.	Bioorg Med Chem.	19(22)	6892-905.	2011
Kadokura M, <u>Maekawa S</u> , Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M, Nakagawa M, Sakamoto N, Watanabe M, Enomoto N.	Analysis of the complete open reading frame of genotype 2b hepatitis C virus in association with the response to peginterferon and ribavirin therapy.	PLoS One.	6(9)	e24514.	2011
Kadokura M, <u>Maekawa S</u> , Sueki R, Miura M, Komase K, Shindo H, Amemiya F, Uetake T, Inoue T, Sakamoto M, Nakagawa M, Sakamoto N, Watanabe M, Enomoto N.	Analysis of the complete open reading frame of hepatitis C virus in genotype 2a infection reveals critical sites influencing the response to peginterferon and ribavirin therapy.	Hepatol Int.	5(3)	789-99.	2011
Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, <u>Maekawa S</u> , Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M.	Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.	J Hepatol.	54(3)	439-48.	2011
Katoh H, Okamoto T, Fukuhara T, Kambara H, Morita E, Mori Y, Kamitani W, <u>Matsuura Y</u> .	Japanese Encephalitis Virus Core Protein Inhibits Stress Granule Formation through an Interaction with Caprin-1 and Facilitates Viral Propagation	J Virol	87	489-502	2013
Suzuki R, Matsuda M, Watashi K, Aizaki H, <u>Matsuura Y</u> , Wakita T, Suzuki T.	Signal peptidase complex subunit 1 participates in the assembly of hepatitis C virus through an interaction with E2 and NS2	PLoS Pathog		doi:10.1371/journal.ppat.1003589	2013

Lee H, Komano J, Saitoh Y, Yamaoka S, Kozaki T, Misawa T, Takahama M, Satoh T, Takeuchi O, Yamamoto N, <u>Matsuura Y</u> , Saitoh T, Akira S.	Zinc-finger antiviral protein mediates retinoic acid inducible gene I-like receptor-independent antiviral response to murine leukemia virus	Proc Natl Acad Sci U S A	110	12379-12384	2013
Yoshio S, Kanto T, Kuroda S, Matsubara T, Higashitani K, Kakita N, Ishida H, Hiramatsu N, Nagano H, Sugiyama M, Murata K, Fukuhara T, <u>Matsuura Y</u> , Hayashi N, Mizokami M, Takehara T.	Human BDCA3 (+) dendritic cells are a potent producer of IFN- λ in response to hepatitis C virus	Hepatology	57	1705-1715	2013
Kimura T, Katoh H, Kayama H, Saiga H, Okuyama M, Okamoto T, Umemoto E, <u>Matsuura Y</u> , Yamamoto M, Takeda K.	Ifit1 inhibits Japanese encephalitis virus replication through binding to 5' capped 2'-O unmethylated RNA	J Virol	87	9997-10003	2013
Tripathi LP, Kambara H, Chen YA, Nishimura Y, Moriishi K, Okamoto T, Morita E, Abe T, Mori Y, <u>Matsuura Y</u> , Mizuguchi K.	Understanding the biological context of NS5A-host interactions in HCV infection: a network-based approach	J Proteome Res	12	2537-2551	2013
Fukuhara T, Kambara H, Shiokawa M, Ono C, Katoh H, Morita E, Okuzaki D, Maehara Y, Koike K, <u>Matsuura Y</u> .	Expression of miR-122 facilitates an efficient replication in nonhepatic cells upon infection with HCV.	J.Virol.	86	7918-7933	2012
Abe T, Fukuhara T, Wen X, Ninomiya A, Moriishi K, Maehara Y, Takeuchi O, Kawai T, Akira S, <u>Matsuura Y</u> .	CD44 participates in the IP-10 induction in cells replicating HCV RNA through an interaction with TLR2 and hyaluronan.	J.Virol.	86	6159-6170	2012
Kambara H, Fukuhara T, Shiokawa M, Ono C, Ohara Y, Kamitani W, <u>Matsuura Y</u> .	Establishment of a novel permissive cell line for propagation of hepatitis C virus by the expression of microRNA122.	J.Virol.	86	1382-1393	2012
Fukuhara T, <u>Matsuura Y</u> .	Role of miR-122 and lipid metabolism in HCV infection.	J. Gastroenterol.		doi:10.1007/s00535-012-0661-5.	2012

Moriishi K, <u>Matsuura Y.</u>	Exploitation of lipid components by viral and host proteins for hepatitis C virus infection.	Front. Microbiol.		doi:10.3389/fmicb.2012.00054.	2012
Suzuki R, Saito K, Kato T, Shirakura M, Akazawa D, Ishii K, Aizaki H, Kanegae Y, <u>Matsuura Y.</u> , Saito I, Wakita T, Suzuki T.	Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection.	Virology	432	29-38	2012
Kobayashi F, Yamada S, Taguwa S, Kataoka C, Naito S, Hama Y, Tani H, <u>Matsuura Y.</u> , Sugahara K.	Specific interaction of the envelope glycoproteins E1 and E2 with liver heparan sulfate involved in the tissue tropism infection by hepatitis C virus.	Glycoconj. J.	29	211-220	2012
Tripathi L.P, Kambara H, Moriishi K, Morita E, Abe T, Mori Y, Chen Y.A, <u>Matsuura Y.</u> , Mizuguchi K.	Proteomic Analysis of Hepatitis C Virus (HCV) Core Protein Transfection and Host Regulator PA28 γ Knockout in HCV Pathogenesis: A Network-Based Study.	J. Proteome Res.	11	3664-3679	2012
Kondo M, Moriishi K, Wada H, Noda T, Marubashi S, Wakasa K, <u>Matsuura Y.</u> , Doki Y, Mori M, Nagano H.	Upregulation of nuclear PA28 γ expression in cirrhosis and hepatocellular carcinoma.	Exp. Ther. Med.	3	379-385	2012
Taguwa S, Kambara H, Fujita N, Noda T, Yoshimori T, Koike K, Moriishi K, <u>Matsuura Y.</u>	Dysfunction of autophagy participates in vacuole formation and cell death in cells replicating hepatitis C virus.	J.Virol.	85	13185-13194	2011
Kato H, Mori Y, Kambara H, Abe T, Fukuhara T, Morita E, Moriishi K, Kamitani W, <u>Matsuura Y.</u>	Heterogeneous nuclear ribonucleoprotein A2 participates in the replication of Japanese encephalitis virus through an interaction with viral proteins and RNA.	J.Virol.	85	10976-10988	2011
Kambara H, Tani H, Mori Y, Abe T, Kato H, Fukuhara T, Taguwa S, Moriishi K, <u>Matsuura Y.</u>	Involvement of cyclophilin B in the replication of Japanese encephalitis virus.	Virology	412	211-219	2011

Wen X, Abe T, Kukihara H, Taguwa S, Mori Y, Tani H, Kato N, Suzuki T, Tatsumi M, Moriishi M, Matsuura Y.	Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules.	PLoS One	6	e15967	2011
Fukuhara T, Tani H, Shiokawa M, Goto Y, Abe T, Taketomi A, Shirabe K, Maehara Y, <u>Matsuura Y.</u>	Intracellular delivery of serum-derived hepatitis C virus.	Microbes Infect.	13	405-412	2011
Ohira M, Nishida S, Matsuura T, Muraoka I, Tryphonopoulos P, Fan J, Tekin A, Selvaggi G, Levi D, Ruiz P, Ricordi C, <u>Ohdan H.</u> Tzakis AG.	Comparative analysis of T-cell depletion method for clinical immunotherapy-anti-hepatitis c effects of natural killer cells via interferon-gamma production.	Transplant Proc.	45(5)	2045-2050	2013
Onoe T, Tanaka Y, Ide K, Ishiyama K, Oshita A, Kobayashi T, Amano H, Tashiro H, <u>Ohdan H.</u>	Attenuation of Portal Hypertension by Continuous Portal Infusion of PGE1 and Immunologic Impact in Adult-to-Adult Living-Donor Liver Transplantation.	Transplantation..	95(12)	1521-1527	2013
<u>大段秀樹</u>	State of the Art 肝免疫と肝臓外科 Liver Immunity and Surgery.	Frontiers in Gastroenterology.	18(3)	203-213	2013
Tashiro H, Ide K, Amano H, Kobayashi T, Onoe T, Ishiyama K, Kuroda S, Tazawa H, Kono H, Aikata H, Takahashi S, Chayama K, <u>Ohdan H.</u>	Surgical treatment for portosystemic encephalopathy in patients with liver cirrhosis: Occlusion of portosystemic shunt in combination with splenectomy.	Hepatol Res.	43(3)	249-254	2013
Iwako H, Tashiro H, Amano H, Tanimoto Y, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Nambu J, Mikuriya Y, Abe T, <u>Ohdan H.</u>	Prognostic significance of antithrombin III levels for outcomes in patients with hepatocellular carcinoma after curative hepatectomy.	Ann Surg Oncol.	19	2888	2012
Oshita A, Tashiro H, Amano H, Kobayashi T, Onoe T, Ide K, Takaki S, Takahashi S, Arihiro K, Chayama K, <u>Ohdan H.</u>	Safety and feasibility of diet-treated donors with steatotic livers at the initial consultation for living-donor liver transplantation.	Transplantation.	93	1024	2012

Ohira M, Nishida S, Tryphonopoulos P, Tekin A, Selvaggi G, Moon J, Levi D, Ricordi C, Ishiyama K, Tanaka Y, <u>Ohdan H</u> , Tzakis AG.	Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.	Cell Transplant	21(7)	1397-1406	2012
Kajitani K, Tanaka Y, Arihiro K, Kataoka T, <u>Ohdan H</u> .	Mechanistic analysis of the antitumor efficacy of human natural killer cells against breast cancer cells.	Breast Cancer Res Treat.	134	139	2012
Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T, Chayama K, <u>Ohdan H</u> .	Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.	Ann Surg Oncol.	19(2)	418-425	2012
Kuroda S, Tashiro H, Igarashi Y, Tanimoto Y, Nambu J, Oshita A, Kobayashi T, Amano H, Tanaka Y, <u>Ohdan H</u> .	Rho inhibitor prevents ischemia-reperfusion injury in rat steatotic liver.	J Hepatol.	56(1)	146-152	2012
Wang C, Wang H, Ide K, Wang Y, Van Rooijen N, <u>Ohdan H</u> , Yang YG.	Human CD47 expression permits survival of porcine cells in immunodeficient mice that express SIRP α capable of binding to human CD47.	Cell Transplant	20	1915-1920	2011
Tashiro H, Ishiyama K, Ohira M, Igarashi Y, Tahara H, Ide K, Onoe T, Tanaka Y, <u>Ohdan H</u> .	Impact of adjuvant immunotherapy using liver allograft-derived lymphocytes on bacteremia in living-donor liver transplantation.	Transplantation.	92(5)	575-580	2011
Ide K, Tanaka Y, Onoe T, Banshodani M, Tazawa H, Igarashi Y, Basnet NB, Dorskali M, Tashiro H, <u>Ohdan H</u> .	Evidence for the immunosuppressive potential of calcineurin inhibitor-sparing regimens in liver transplant recipients with impaired renal function.	J Transplant			2011
Amano H, Hino H, Tateno C, Emoto K, Imaoka Y, Yamasaki C, Itamoto T, Tashiro H, Asahara T, <u>Ohdan H</u> , Yoshizato K.	Therapeutic potential of propagated hepatocyte transplantation in liver failure.	J Surg Res.	167(1)	e29-37	2011

Nakajima S, Watashi K, Kamisuki S, Tsukuda S, Takemoto K, Matsuda M, Suzuki R, Aizaki H, Sugawara F, <u>Wakita T.</u>	Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives.	Biochem Biophys Res Commun.	440(4)	515-20.	2013
Suzuki R, Matsuda M, Watashi K, Aizaki H, Matsuura Y, <u>Wakita T.</u> , Suzuki T.	Signal Peptidase Complex Subunit 1 Participates in the Assembly of Hepatitis C Virus through an Interaction with E2 and NS2.	PLoS Pathog.	(8)	e1003589.	2013
Maehama T, Fukasawa M, Date T, <u>Wakita T.</u> , Hanada K.	A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication.	Biochem Biophys Res Commun.	440(1)	150-156.	2013
Matsumoto Y, Matsuura T, Aoyagi H, Matsuda M, Hmwe SS, Date T, Watanabe N, Watashi K, Suzuki R, Ichinose S, Wake K, Suzuki T, Miyamura T, <u>Wakita T.</u> , Aizaki H.	Antiviral Activity of Glycyrrhizin against Hepatitis C Virus In Vitro.	PLoS One.	8(7)	e68992.	2013
Akazawa D, Moriyama M, Yokokawa H, Omi N, Watanabe N, Date T, Morikawa K, Aizaki H, Ishii K, Kato T, Mochizuki H, Nakamura N, <u>Wakita T.</u>	Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.	Gastroenterology.	145(2):	447-455.e4.	2013
Sekiguchi S, Kimura K, Chiyo T, Ohtsuki T, Tobita Y, Tokunaga Y, Yasui F, Tsukiyama-Kohara K, <u>Wakita T.</u> , Tanaka T, Miyasaka M, Mizuno K, Hayashi Y, Hishima T, Matsushima K, Kohara M	Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver	PLoS One.	7(12)	e51656.	2012
Murakami Y, Fukasawa M, Kaneko Y, Suzuki T, <u>Wakita T.</u> , Fukazawa H.	Selective estrogen receptor modulators inhibit hepatitis C virus infection at multiple steps of the virus life cycle.	Microbes Infect.	15(1)	45-55.	2013
Saeed M, Gondeau C, Hmwe S, Yokokawa H, Date T, Suzuki T, Kato T, Maurel P, <u>Wakita T.</u>	Replication of hepatitis C virus genotype 3a in cultured cells.	Gastroenterology.	144(1)	56-58.e7	2013

Date T, Kato T, Kato J, Takahashi H, Morikawa K, Akazawa D, Murayama A, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, <u>Wakita T.</u>	Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone.	J Virol.	86(19)	10805-20.	2012
Suzuki R, Saito K, Kato T, Shirakura M, Akazawa D, Ishii K, Aizaki H, Kanegae Y, Matsuura Y, Saito I, <u>Wakita T.</u> Suzuki T.	Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection.	Virology.	432(1)	29-38.	2012
Ando T, Imamura H, Suzuki R, Aizaki H, Watanabe T, <u>Wakita T.</u> Suzuki T.	Visualization and measurement of ATP levels in living cells replicating hepatitis C virus genome RNA.	PLoS Pathog.	8(3)	e1002561.	2012
Date T, Morikawa K, Tanaka Y, Tanaka-Kaneko K, Sata T, Mizokami M, <u>Wakita T.</u>	Replication and infectivity of a novel genotype 1b hepatitis C virus clone.	Microbiol Immunol.	56(5)	308-17.	2012
Weng L, Kohara M, <u>Wakita T.</u> Shimotohno K, Toyoda T.	Detergent-induced activation of the hepatitis C virus genotype 1b RNA polymerase.	Gene.	496(2)	79-87.	2012
Murayama A, Kato T, Akazawa D, Sugiyama N, Date T, Masaki T, Nakamoto S, Tanaka Y, Mizokami M, Yokosuka O, Nomoto A, <u>Wakita T.</u>	Production of Infectious Chimeric Hepatitis C Virus Genotype 2b Harboring Minimal Regions of JFH-1.	J Virol.	86(4)	2143-52.	2012
Salim MT, Aoyama H, Sugita K, Watashi K, <u>Wakita T.</u> Hamasaki T, Okamoto M, Urata Y, Hashimoto Y, Baba M.	Potent and selective inhibition of hepatitis C virus replication by novelphenanthridinone derivatives.	Biochem Biophys Res Commun.	415(4)	714-9.	2011
Sugiyama M, Tanaka Y, <u>Wakita T.</u> Nakanishi M, Mizokami M.	Genetic Variation of theIL-28B Promoter Affecting Gene Expression.	PLoS One.	6(10)	e26620.	2011
Arnaud N, Dabo S, Akazawa D, Fukasawa M, Shinkai-Ouchi F, Hugon J, <u>Wakita T.</u> Meurs EF.	Hepatitis C virus reveals a novel early control in acute immune response.	PLoS Pathog.	7(10)	e1002289.	2011

Saeed M, Suzuki R, Watanabe N, Masaki T, Tomonaga M, Muhammad A, Kato T, Matsuura Y, Watanabe H, <u>Wakita T</u> , Suzuki T.	Role of the endoplasmic reticulum-associated degradation (ERAD) pathway in degradation of hepatitis C virus envelope proteins and production of virus particles.	J Biol Chem.	286(43)	37264-73.	2011
Okamoto Y, Masaki T, Murayama A, Munakata T, Nomoto A, Nakamoto S, Yokosuka O, Watanabe H, <u>Wakita T</u> , Kato T.	Development of recombinant hepatitis C virus with NS5A from strains of genotypes 1 and 2.	Biochem Biophys Res Commun.	410(3)	404-9.	2011
Yamamoto M, Aizaki H, Fukasawa M, Teraoka T, Miyamura T, <u>Wakita T</u> , Suzuki T.	Structural requirements of virion-associated cholesterol for infectivity, buoyant density and apolipoprotein association of hepatitis C virus.	J Gen Virol.	92(Pt 9)	2082-7.	2011
Akazawa D, Morikawa K, Omi N, Takahashi H, Nakamura N, Mochizuki H, Date T, Ishii K, Suzuki T, <u>Wakita T</u> .	Production and characterization of HCV particles from serum-free culture.	Vaccine.	29(29-30)	4821-8.	2011
Saeed M, Shiina M, Date T, Akazawa D, Watanabe N, Murayama A, Suzuki T, Watanabe H, Hiraga N, Imamura M, Chayama K, Choi Y, Krawczynski K, Liang TJ, <u>Wakita T</u> , Kato T.	In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis.	Hepatology.	54(2)	425-33.	2011
Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, <u>Wakita T</u> , Kaneko S; Hokuriku Liver Study Group.	Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C.	Gastroenterol.	141(1)	128-40, 140.e1-2.	2011

Aly HH, Oshiumi H, Shime H, Matsumoto M, <u>Wakita T</u> , Shimotohno K, Seya T.	Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV).	PLoS One.	6(6)	e21284.	2011
--	---	-----------	------	---------	------